Diligence memo · auto-generated · as of July 2, 2026
RNAissance AG LLC
RNAissance AG LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
RNAissance AG LLC operates in Biotechnology, based in ST. LOUIS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
RNAissance AG LLC has raised $990K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $990K on 2020-06-05.
Most recent recorded round closed around 2020-06-05.
Valuation (modeled)modeled
Provath models RNAissance AG LLC at approximately $55M (range $528K–$620M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.51× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 6.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 17% of Biotechnology peers (4293 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, Pylum Biosciences, Inc., NanoTomer, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.